NCT01615874撤回2 期
A Six-week Evaluator-Blind, Randomized, Active-Controlled Evaluation of the Effects of Three Doses of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI), Montelukast, and Beclomethasone Dipropionate (BDP HFA) on the HPA Axis in Asthmatic Children 5 to 11 Years of Age (Protocol No. P05574/PN158)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 主要终点
- Change from Baseline in Plasma Cortisol Area Under the Curve (AUC) 0-24 hrs
研究概览
简要总结
The purpose of this study is to assess the effect of one of five possible study medications used in the treatment of asthma on blood plasma cortisol levels in children aged 5-11 years with persistent asthma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 5 Years 至 11 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •diagnosis of persistent asthma of ≥6 months duration
- •body weight ≥18 kg
- •able to discontinue prescribed inhaled corticosteroid (ICS) or ICS combined with long-acting beta-agonist (LABA) before starting study medication
- •use of a low or medium daily dose of ICS (either alone or in combination with a LABA) with no use of oral corticosteroids within 3 months prior to Screening Visit
- •stable asthma regimen (daily dose unchanged) for ≥2 weeks prior to Screening Visit
- •documented positive responsiveness to bronchodilators
- •ability to use a peak flow meter correctly and to perform spirometry and PEF measurements
- •ability to use an inhaler correctly
- •consent/assent for the trial and for pharmacogenetic testing (Note: If unwilling to consent/assent for pharmacogenetic testing, inclusion in the study is still allowed, but no pharmacogenetic samples will be obtained.)
排除标准
- •use of a high dose of ICS for ≥30 days within 6 months prior to Screening Visit
- •treatment in the emergency room (for a severe asthma exacerbation requiring systemic corticosteroid treatment) or hospitalization for management of airway obstruction within 3 months prior to Screening Visit
- •ever required ventilator support for respiratory failure secondary to asthma
- •upper or lower respiratory tract infection (viral or bacterial) within 2 weeks prior to Screening Visit
- •clinically significant abnormal vital sign
- •evidence of oropharyngeal candidiasis
- •history of clinically significant renal, hepatic, cardiovascular, metabolic, neurologic, hematologic, ophthalmologic, respiratory, gastrointestinal, cerebrovascular, or other significant medical illness or disorder that may interfere with study participation. Specific examples include but are not limited to insulin-dependent diabetes, active hepatitis, cardiovascular disease including hypertension, or conditions that may interfere with respiratory function such as, bronchiectasis, and cystic fibrosis
- •allergy to or intolerance of corticoids, beta-2 agonists, montelukast or any of the inactive ingredients in the medications used in this study
- •participation in this same study at another study site
- •previous randomization into this study
- •participation in another investigational study for the duration of this study
- •use of any investigational drug within one month prior to Screening Visit
- •previous participation in a study with MF/F or montelukast
- •direct association with or family member of one of the investigators or study staff
- •sibling of a participant in this study
研究组 & 干预措施
MF/F MDI 50/10 mcg BID
Experimental
干预措施: MF/F Metered Dose Inhaler (MDI) 25/5 mcg (Drug)
MF/F MDI 100/10 mcg BID
Experimental
干预措施: MF/F MDI 50/5 mcg (Drug)
MF/F MDI 200/10 mcg BID
Experimental
干预措施: MF/F MDI 100/5 mcg (Drug)
BDP HFA 160 mcg BID
Active Comparator
干预措施: BDP hydrofluoroalkane (HFA) 80 mcg (Drug)
Montelukast 5 mg QD (4 mg QD for 5-year-olds)
Active Comparator
干预措施: Montelukast tablets 5 mg (4 mg for children 5 years of age) (Drug)
结局指标
主要结局
Change from Baseline in Plasma Cortisol Area Under the Curve (AUC) 0-24 hrs
时间窗: Baseline (Day 1) and Day 42
次要结局
- Change from Baseline in Plasma Cortisol Trough Concentration (Ctrough)(Baseline (Day 1) and Day 42)
研究者
相似试验
已完成
2 期
Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn's DiseaseCrohn DiseaseNCT00102921Amgen70
已完成
3 期
A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-076)(COMPLETED)OsteoarthritisNCT00092768Organon and Co500
已完成
3 期
A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-077)(COMPLETED)OsteoarthritisNCT00092781Organon and Co500
已完成
3 期
An Approved Drug to Study a New Indication for Seasonal Allergic Rhinitis in Patients With Asthma (0476-269)Rhinitis, Allergic, SeasonalAsthma, BronchialNCT00092885Organon and Co831
已完成
3 期
An Investigational Drug in Patients With Osteoarthritis (0663-073)OsteoarthritisNCT00092755Organon and Co548